Clinical trials: Lung; Disease, Interstitial, With Fibrosis
Idiopathic Pulmonary Fibrosis
A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are at least 40 years old. People taking standard medicines for IPF, including antifibrotic medicines, can continue taking them throughout the study.
- Trial name
- NCT04419506
- Testing
- BI 1015550
- Where
- 75 sites in United States, Argentina and 20 more
- Volunteers
- 147 people
- Sponsor
- Boehringer Ingelheim
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital
The study to evaluate the effect of cyclosporine ( IL2 inhibitor and antiviral) verse standard care treatment on decrease ADRS, hyper inflammation, hypercytokinemia, and the mortality rate
- Conditions
- COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Pulmonary Fibrosis
- Trial name
- NCT04979884
- Testing
- cyclosporine
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Alexandria University
Idiopathic Pulmonary Fibrosis
Study of ORJ-001 for the Treatment of IPF
ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by…
- Trial name
- NCT07869147
- Testing
- ORJ-001
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Oorja Bio, Inc.
Pulmonary Fibrosis
Pulmonary Fibrosis and Telomerase Mutation Study
This study is an observational and retrospective study of patients with pulmonary fibrosis associated or not with telomerase mutation.
- Trial name
- NCT01501578
- Where
- France
- Volunteers
- 81 people
- Sponsor
- Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease
Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial
The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease, Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- OPTIMIZE-ILD-1 (NCT07482917)
- Testing
- Standard ILD Diagnostic Pathway, Optimized ILD Diagnostic Circuit
- Where
- Spain
- Volunteers
- 92 people
- Sponsor
- Hospital de Granollers
Idiopathic Pulmonary Fibrosis, Depression
Palliative Care and Quality of Life in Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the effects of adding a palliative care intervention for patients with idiopathic pulmonary fibrosis (IPF) to current standard of care.
- Conditions
- Idiopathic Pulmonary Fibrosis, Depression, Anxiety, Depressive Disorder
- Trial name
- NCT03981406
- Testing
- Palliative Care, Standard of Care
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Minnesota
Breast Neoplasms, Radiation Pneumonia
Radiotherapy Exposed Lung Injury: Effect on Functioning - Cohort
Prospective cohort research to study the state of oxygen metabolism, reserve capabilities of cardiovascular and respiratory systems in patients with breast cancer to create a program of prevention and rehabilitation of lung…
- Conditions
- Breast Neoplasms, Radiation Pneumonia, Radiation Pneumonitis, Radiation Induced Fibrosis
- Trial name
- RELIEF-COHORT (NCT06069115)
- Testing
- Radiation therapy protocol for Breast cancer, Spirography and assessment of pulmonary diffusion capacity, Cardiopulmonary stress test
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Idiopathic Pulmonary Fibrosis
A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 2, randomized, double-blind, placebo-controlled safety and tolerability study of N-acetylcysteine or placebo in participants with mild to moderate idiopathic pulmonary fibrosis (IPF) receiving background…
- Trial name
- NCT02707640
- Testing
- N-acetylcysteine, Pirfenidone
- Where
- 69 sites in Austria, Belgium and 6 more
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Pulmonary Hypertension, Pulmonary Fibrosis
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
This multicenter, randomized, open-label study will assess the safety and efficacy of oral treprostinil in subjects diagnosed with pulmonary hypertension associated with pulmonary fibrosis.
- Trial name
- NCT02603068
- Testing
- Oral treprostinil
- Where
- 7 sites in United States
- Sponsor
- United Therapeutics
Idiopathic Pulmonary Fibrosis
Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib
Multi-center, non-interventional, prospective cohort study aiming to enroll 240 Idiopathic Pulmonary Fibrosis patients receiving treatment with nintedanib in a consecutive manner from 10-12 reference centers across Greece.
- Trial name
- QUALIFY IPF (NCT03710824)
- Testing
- Nintedanib
- Where
- 10 sites in Greece
- Volunteers
- 180 people
- Sponsor
- Boehringer Ingelheim
Fibrosis, Pulmonary
Rehabilitation Counselling for Patients with Interstitial Lung Disease
Idiopathic pulmonary fibrosis (IPF) is a rare chronic progressive disease of unknown etiology that affects physical and emotional well-being.
- Trial name
- NCT06815185
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Idiopathic Pulmonary Fibrosis
Acute Effects of Oxygen Supplementation Among IPF Patients
Idiopathic pulmonary fibrosis (IPF) is a disease characterised with significant morbidity and poor prognosis. Dyspnoea and impaired exercise capacity are very common manifestations of the disease, and result in significant…
- Trial name
- NCT03688334
- Testing
- Oxygen 40 %
- Where
- Greece
- Volunteers
- 15 people
- Sponsor
- George Papanicolaou Hospital
Lung Diseases, Interstitial
Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment
The primary objective for this trial is to investigate the incidence probability of progression to Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) in patients with fibrosing ILD other than Idiopathic Pulmonary Fibrosis…
- Trial name
- NCT05875532
- Where
- United States
- Volunteers
- 34,960 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
The objectives of this study are to assess the safety and efficacy of treatment with pirfenidone 2403 milligrams per day (mg/d) compared with placebo in patients with idiopathic pulmonary fibrosis (IPF), to assess the safety and…
- Trial name
- NCT00287716
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 435 people
- Sponsor
- Genentech, Inc.
Interstitial Lung Disease Due to Systemic Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis
Physical Exercise Program for Adults With Diffuse Interstitial Lung Disease in a Pulmonary Rehabilitation Context
This study aims to evaluate the effectiveness of an exercise program that includes three exercise modalities (Aerobic, Limb Strength and Respiratory Muscle Strength) versus an exercise program that includes only one modality…
- Conditions
- Interstitial Lung Disease Due to Systemic Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Pulmonary Fibrosis
- Trial name
- NCT07061873
- Testing
- Aerobic excersise, Muscle strength limbs, inspiratory muscle strength
- Where
- Chile
- Volunteers
- 29 people
- Sponsor
- Universidad de La Frontera
Idiopathic Pulmonary Fibrosis
SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Evaluating Sufenidone (SC1011) in IPF patients for efficacy and safety. Includes screening, treatment, and follow-up, with FVC decline and health checks.
- Trial name
- NCT06125327
- Testing
- SC1011
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Idiopathic Pulmonary Fibrosis, Mechanical Ventilation Pressure High
End-expiratory Trans-pulmonary Pressure Guided PEEP Titration in Patients With Pulmonary Fibrosis and UIP Pattern Undergoing Mechanical Ventilation
Patients with pulmonary fibrosis and associated usual interstitial pneumonia that require mechanical ventilation for acute respiratory failure experience poor clinical outcomes.
- Trial name
- ETROPON (NCT05098717)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- University of Modena and Reggio Emilia
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis.
- Trial name
- IPF/ILD-PRO (NCT01915511)
- Where
- 47 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Duke University
Interstitial Lung Disease, Interstitial Pneumonia
Clinical Characteristics of Interstitial Pneumonia With Autoimmune Features (IPAF) - a Multicenter Prospective Study
Interstitial pneumonia with autoimmune features (IPAF) was defined in 2015 by the Working Group of the European Respiratory Society (ERS) and the American Thoracic Society (ATS) as interstitial pneumonia with some clinical and/or…
- Conditions
- Interstitial Lung Disease, Interstitial Pneumonia, Interstitial Fibrosis, Autoimmune Diseases
- Trial name
- NCT03870828
- Testing
- Bronchoalveolar lavage and taking bronchial mucosa samples, 6minute walk test, Arterial blood gas
- Where
- 7 sites in Italy, Poland
- Volunteers
- 210 people
- Sponsor
- Medical University of Silesia
Cystic Fibrosis, Hemophilia A
Medication Adherence and Non-adherence in Adults With Rare Disease
The purpose of this study is to use the Medication Adherence Reasons Scale (MAR-Scale) to determine the extent of non-adherence to specific medications indicated to treat cystic fibrosis, hemophilia (A or B), idiopathic pulmonary…
- Conditions
- Cystic Fibrosis, Hemophilia A, Hemophilia B, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT04541875
- Testing
- MAR-Scale
- Volunteers
- healthy volunteers welcome
- Sponsor
- Xperiome